title: Serotonin syndrome due to association of venlafaxine, maprotiline and reboxetine.
authors.forename: José-Manuel
authors.initials: JM
authors.lastname: Bertolín-Guillén
authors.forename: Benjamín
authors.initials: B
authors.lastname: Climent-Díaz
authors.forename: Arancha
authors.initials: A
authors.lastname: Navarré-Gimeno
mesh_terms: D003511:Cyclohexanols / Q000009:adverse effects* / Q000627:therapeutic use; D003866:Depressive Disorder / Q000188:drug therapy*; D004632:Emergency Medical Services; D006801:Humans; D008297:Male; D008376:Maprotiline / Q000009:adverse effects* / Q000627:therapeutic use; D008875:Middle Aged; D009025:Morpholines / Q000009:adverse effects* / Q000627:therapeutic use; D000077593:Reboxetine; D020230:Serotonin Syndrome / Q000139:chemically induced* / Q000534:rehabilitation; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D000069470:Venlafaxine Hydrochloride
chemical_list: D003511:Cyclohexanols; D008376:Maprotiline; D009025:Morpholines; D000077593:Reboxetine; D017367:Selective Serotonin Reuptake Inhibitors; D000069470:Venlafaxine Hydrochloride